Mercer Global Advisors Inc. ADV Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Mercer Global Advisors Inc. ADV lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 21.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,043 shares of the medical research company’s stock after buying an additional 2,277 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in IQVIA were worth $2,746,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc raised its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the 2nd quarter worth about $27,000. Rise Advisors LLC purchased a new stake in IQVIA during the 1st quarter valued at about $31,000. Riverview Trust Co acquired a new position in shares of IQVIA in the first quarter valued at about $32,000. Finally, International Assets Investment Management LLC purchased a new position in shares of IQVIA in the second quarter worth about $32,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.0 %

Shares of NYSE:IQV opened at $242.12 on Monday. The business’s 50 day moving average price is $240.60 and its 200-day moving average price is $233.94. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a market capitalization of $44.14 billion, a price-to-earnings ratio of 33.08, a price-to-earnings-growth ratio of 2.25 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same quarter last year, the business earned $2.22 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of several research reports. Morgan Stanley increased their price target on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Robert W. Baird raised their target price on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday. UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada started coverage on IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price on the stock. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $267.00.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.